GlassScriptPhysician profile
Katherine H Brewer
NPI 1316924376
$17,087.50
in general payments reported to CMS, 2019-2025
17 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $192 · 2021: $814 · 2022: $579 · 2023: $526 · 2024: $698 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.98 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,642.06 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Optinose US, INC. | $3,433.96 | 2019 | |
| Phadia US INC. | $1,312.46 | 2019-2024 | Immunocap |
| Genzyme Corporation | $441.27 | 2021-2025 | |
| Alk-Abello, INC | $437.95 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.53 | 2019-2023 | Spiriva Respimat |
| Glaxosmithkline, LLC. | $286.38 | 2019-2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $232.81 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $188.07 | 2021-2022 | |
| Kaleo, INC. | $175.82 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $160.66 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $134.70 | 2021-2023 | Airduo Digihaler |
| Janssen Pharmaceuticals, INC | $109.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Dermavant Sciences, INC. | $25.77 | 2024 | Vtama |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.83 | 2019 | |
| Amgen INC. | $18.69 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.